Thank you to all the ALS patients who have volunteered to participate in the Cytokinetics Phase III clinical trial of tirasemtiv in ALS at the Lois Insolia ALS Clinic at the Les Turner ALS Research and Patient Center at Northwestern Medicine. The Lois Insolia ALS Clinic was the only clinic in Illinois to offer this clinical trial. Cytokinetics has just announced completion of enrollment of 700 patients worldwide. The company is testing the drug’s effect on respiratory function in ALS patients, following evidence of improvement in slow vital capacity (SVC) in the Phase II trial. We look forward to hearing the results of the trial in the second half of 2017.
A press release with more information on the announcement can be found here.